Bio-Path (NASDAQ:BPTH) Coverage Initiated by Analysts at

Stock analysts at started coverage on shares of Bio-Path (NASDAQ:BPTHGet Free Report) in a report released on Wednesday. The brokerage set a “sell” rating on the stock.

Separately, Roth Mkm reissued a “buy” rating and issued a $40.00 price objective on shares of Bio-Path in a research report on Thursday, April 18th.

View Our Latest Analysis on Bio-Path

Bio-Path Trading Down 8.0 %

BPTH stock opened at $2.69 on Wednesday. Bio-Path has a 12 month low of $2.60 and a 12 month high of $44.80. The company has a 50-day moving average price of $5.14 and a 200 day moving average price of $8.46. The stock has a market cap of $1.83 million, a PE ratio of -0.07 and a beta of 0.36.

Bio-Path (NASDAQ:BPTHGet Free Report) last released its quarterly earnings results on Friday, March 8th. The company reported ($5.40) EPS for the quarter, hitting analysts’ consensus estimates of ($5.40). During the same quarter in the previous year, the firm earned ($10.60) EPS. Sell-side analysts forecast that Bio-Path will post -18.71 EPS for the current year.

About Bio-Path

(Get Free Report)

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

Featured Stories

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with's FREE daily email newsletter.